Logo image of STRO

SUTRO BIOPHARMA INC (STRO) Stock Fundamental Analysis

NASDAQ:STRO - Nasdaq - US8693671021 - Common Stock - Currency: USD

0.7991  -0.01 (-1.5%)

After market: 0.7991 0 (0%)

Fundamental Rating

1

Taking everything into account, STRO scores 1 out of 10 in our fundamental rating. STRO was compared to 559 industry peers in the Biotechnology industry. STRO may be in some trouble as it scores bad on both profitability and health. STRO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

STRO had negative earnings in the past year.
STRO had a negative operating cash flow in the past year.
STRO had negative earnings in each of the past 5 years.
In the past 5 years STRO reported 4 times negative operating cash flow.
STRO Yearly Net Income VS EBIT VS OCF VS FCFSTRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -76.29%, STRO is not doing good in the industry: 68.16% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -76.29%
ROE N/A
ROIC N/A
ROA(3y)-36.91%
ROA(5y)-29.96%
ROE(3y)-212.09%
ROE(5y)-137.55%
ROIC(3y)N/A
ROIC(5y)N/A
STRO Yearly ROA, ROE, ROICSTRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for STRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STRO Yearly Profit, Operating, Gross MarginsSTRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

STRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STRO has been increased compared to 1 year ago.
Compared to 5 years ago, STRO has more shares outstanding
STRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STRO Yearly Shares OutstandingSTRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
STRO Yearly Total Debt VS Total AssetsSTRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

STRO has an Altman-Z score of -5.21. This is a bad value and indicates that STRO is not financially healthy and even has some risk of bankruptcy.
STRO has a worse Altman-Z score (-5.21) than 60.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.21
ROIC/WACCN/A
WACC9.69%
STRO Yearly LT Debt VS Equity VS FCFSTRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.16 indicates that STRO has no problem at all paying its short term obligations.
With a Current ratio value of 2.16, STRO is not doing good in the industry: 73.70% of the companies in the same industry are doing better.
A Quick Ratio of 2.16 indicates that STRO has no problem at all paying its short term obligations.
STRO has a worse Quick ratio (2.16) than 71.91% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.16
STRO Yearly Current Assets VS Current LiabilitesSTRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

STRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.51%.
The Revenue for STRO has decreased by -56.88% in the past year. This is quite bad
STRO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.74% yearly.
EPS 1Y (TTM)-58.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.21%
Revenue 1Y (TTM)-56.88%
Revenue growth 3Y0.09%
Revenue growth 5Y7.74%
Sales Q2Q%33.76%

3.2 Future

The Earnings Per Share is expected to grow by 14.52% on average over the next years. This is quite good.
STRO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.83% yearly.
EPS Next Y37.75%
EPS Next 2Y25.57%
EPS Next 3Y15.28%
EPS Next 5Y14.52%
Revenue Next Year-4.12%
Revenue Next 2Y-14.44%
Revenue Next 3Y-9.96%
Revenue Next 5Y-1.83%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
STRO Yearly Revenue VS EstimatesSTRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
STRO Yearly EPS VS EstimatesSTRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STRO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STRO Price Earnings VS Forward Price EarningsSTRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STRO Per share dataSTRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as STRO's earnings are expected to grow with 15.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.57%
EPS Next 3Y15.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for STRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUTRO BIOPHARMA INC

NASDAQ:STRO (6/13/2025, 8:00:01 PM)

After market: 0.7991 0 (0%)

0.7991

-0.01 (-1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners78.33%
Inst Owner Change-0.97%
Ins Owners0.82%
Ins Owner Change6.28%
Market Cap67.49M
Analysts72.94
Price Target3.32 (315.47%)
Short Float %8.51%
Short Ratio4.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.54%
Min EPS beat(2)-26.1%
Max EPS beat(2)-4.99%
EPS beat(4)2
Avg EPS beat(4)4.29%
Min EPS beat(4)-26.1%
Max EPS beat(4)26.97%
EPS beat(8)4
Avg EPS beat(8)23.06%
EPS beat(12)5
Avg EPS beat(12)17.38%
EPS beat(16)6
Avg EPS beat(16)15.62%
Revenue beat(2)2
Avg Revenue beat(2)31.83%
Min Revenue beat(2)16.74%
Max Revenue beat(2)46.91%
Revenue beat(4)3
Avg Revenue beat(4)9.58%
Min Revenue beat(4)-45.24%
Max Revenue beat(4)46.91%
Revenue beat(8)6
Avg Revenue beat(8)112.14%
Revenue beat(12)9
Avg Revenue beat(12)85.55%
Revenue beat(16)10
Avg Revenue beat(16)67.45%
PT rev (1m)-23.36%
PT rev (3m)-71.68%
EPS NQ rev (1m)30.41%
EPS NQ rev (3m)48.96%
EPS NY rev (1m)16.18%
EPS NY rev (3m)39.36%
Revenue NQ rev (1m)22.46%
Revenue NQ rev (3m)56.45%
Revenue NY rev (1m)19.99%
Revenue NY rev (3m)4.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.98
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-2.35
FCFYN/A
OCF(TTM)-2.31
OCFYN/A
SpS0.79
BVpS-0.31
TBVpS-0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.91%
ROA(5y)-29.96%
ROE(3y)-212.09%
ROE(5y)-137.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52%
Cap/Sales 5.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.16
Altman-Z -5.21
F-Score2
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)81.45%
Cap/Depr(5y)145.34%
Cap/Sales(3y)6.47%
Cap/Sales(5y)12.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.21%
EPS Next Y37.75%
EPS Next 2Y25.57%
EPS Next 3Y15.28%
EPS Next 5Y14.52%
Revenue 1Y (TTM)-56.88%
Revenue growth 3Y0.09%
Revenue growth 5Y7.74%
Sales Q2Q%33.76%
Revenue Next Year-4.12%
Revenue Next 2Y-14.44%
Revenue Next 3Y-9.96%
Revenue Next 5Y-1.83%
EBIT growth 1Y-121.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.12%
EBIT Next 3Y17.09%
EBIT Next 5YN/A
FCF growth 1Y-574.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-777.74%
OCF growth 3YN/A
OCF growth 5YN/A